Here are five things to know:
1. Cerapedics will offer its proprietary synthetic small peptide, P-15, technology and DSM will provide its regenerative materials portfolio.
2. DSM has a bioceramic platform featuring a carbonated apatite matrix.
3. Cerapedics’ P-15 technology promotes bone growth from cell attraction to attachment to activation.
4. Cerapedics’ i-FACTOR Peptide Enhanced Bone Graft has been on the U.S. market since 2008. i-FACTOR was approved for anterior cervical discectomy and fusion in 2015.
5. The next-generation technology will focus on the lumbar spine.
More articles on devices:
DePuy Synthes launches 3-D circular fixation device: 5 insights
Drs. Nick Theodore, Ali Bydon, Kade Huntsman perform 1st surgeries using Globus Medical’s ExcelsiusGPS: 5 takeaways
Medicrea unveils UNiD HUB in Europe: 5 insights
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
